Brokers Set Expectations for Co-Diagnostics FY2025 Earnings

Co-Diagnostics, Inc. (NASDAQ:CODX) – Analysts at HC Wainwright raised their FY2025 EPS estimates for Co-Diagnostics in a note issued to investors on Monday, November 24th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.72) per share for the year, up from their previous estimate of ($0.79). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Co-Diagnostics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Co-Diagnostics’ Q4 2025 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.36) EPS.

Co-Diagnostics (NASDAQ:CODX) last issued its earnings results on Thursday, November 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. The company had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.30 million. Co-Diagnostics had a negative return on equity of 70.26% and a negative net margin of 6,347.34%.

A number of other equities analysts have also issued reports on the stock. D. Boral Capital reissued a “buy” rating and set a $3.00 price target on shares of Co-Diagnostics in a research report on Tuesday, October 28th. Wall Street Zen upgraded shares of Co-Diagnostics to a “hold” rating in a research report on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Co-Diagnostics in a report on Thursday, October 30th. Finally, Maxim Group upgraded Co-Diagnostics to a “hold” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $1.83.

Co-Diagnostics Stock Up 14.9%

Co-Diagnostics stock opened at $0.37 on Wednesday. The stock has a 50-day moving average price of $0.40 and a 200 day moving average price of $0.33. The company has a market capitalization of $22.73 million, a price-to-earnings ratio of -0.38 and a beta of 0.98. Co-Diagnostics has a 52 week low of $0.23 and a 52 week high of $1.55.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Co-Diagnostics stock. Virtu Financial LLC boosted its stake in Co-Diagnostics, Inc. (NASDAQ:CODX) by 393.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 126,524 shares of the company’s stock after acquiring an additional 100,901 shares during the quarter. Virtu Financial LLC owned 0.21% of Co-Diagnostics worth $44,000 as of its most recent filing with the SEC. 14.99% of the stock is currently owned by hedge funds and other institutional investors.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.